Metropolis Healthcare Ltd

Metropolis Healt Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Metropolis Healthcare Ltd

₹ 541 -2.61%
01 Jun - close price
metropolisindia.com BSE: 542650 NSE: METROPOLIS
About

Metropolis Healthcare Limited is one of the leading Indian diagnostics companies. The Company owns a chain of diagnostic centres across India, South Asia, Africa and the Middle East.

Key Points

Leading Diagnostics company[1] Metropolis Healthcare Ltd is the second largest Diagnostic company in India and the largest player in Western and Southern India.

Website BSE NSE
  • Market Cap ₹ 11,264 Cr.
  • Current Price ₹ 541
  • High / Low ₹ 600 / 411
  • Stock P/E 57.4
  • Book Value ₹ 73.0
  • Dividend Yield 0.37 %
  • ROCE 17.8 %
  • ROE 13.8 %
  • Face Value ₹ 2.00
Edit ratios

Pros

Cons

  • Stock is trading at 7.41 times its book value
  • The company has delivered a poor sales growth of 10.5% over past five years.
  • Company has a low return on equity of 12.6% over last 3 years.
  • Dividend payout has been low at 5.35% of profits over last 3 years

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Healthcare Services Healthcare Service Provider

Part of BSE 500 BSE Healthcare BSE 250 SmallCap Index BSE 400 MidSmallCap Index Nifty Microcap 250

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
283 277 308 291 331 313 350 323 345 386 429 406 425
212 214 234 226 251 235 260 251 283 296 321 311 317
Operating Profit 70 63 75 65 80 79 90 72 62 90 108 95 108
OPM % 25% 23% 24% 22% 24% 25% 26% 22% 18% 23% 25% 23% 25%
1 3 1 2 3 2 3 3 7 8 1 -0 8
Interest 6 6 6 5 6 5 5 5 5 5 6 6 8
Depreciation 23 21 22 25 26 26 27 28 29 31 32 32 39
Profit before tax 42 39 48 37 51 51 61 42 36 61 71 57 70
Tax % 20% 26% 26% 26% 28% 25% 24% 26% 19% 26% 26% 26% 27%
33 29 36 27 37 38 47 31 29 45 53 42 51
EPS in Rs 1.63 1.41 1.73 1.33 1.78 1.85 2.27 1.53 1.41 2.17 2.54 2.00 2.46
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
456 475 545 647 761 856 998 1,228 1,148 1,208 1,331 1,646
339 359 405 467 559 619 708 880 855 920 1,023 1,245
Operating Profit 117 116 140 181 203 237 290 348 293 288 308 401
OPM % 26% 24% 26% 28% 27% 28% 29% 28% 26% 24% 23% 24%
7 29 39 6 8 -17 12 34 15 9 15 17
Interest 2 2 2 4 4 13 12 25 32 28 24 25
Depreciation 21 17 17 19 20 39 46 63 89 94 109 134
Profit before tax 101 128 160 164 187 169 244 293 188 175 191 259
Tax % 33% 36% 33% 32% 34% 24% 25% 27% 24% 26% 24% 26%
68 82 107 112 124 128 183 215 143 128 146 191
EPS in Rs 15.44 20.10 26.61 27.29 5.99 6.29 8.95 10.46 6.98 6.24 7.00 9.17
Dividend Payout % 0% 100% 49% 0% 55% 32% 22% 19% 29% 16% 0% 0%
Compounded Sales Growth
10 Years: 13%
5 Years: 11%
3 Years: 13%
TTM: 24%
Compounded Profit Growth
10 Years: 11%
5 Years: 1%
3 Years: 11%
TTM: 40%
Stock Price CAGR
10 Years: %
5 Years: -3%
3 Years: 18%
1 Year: 29%
Return on Equity
10 Years: 19%
5 Years: 15%
3 Years: 13%
Last Year: 14%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 10 10 10 10 10 10 10 10 10 10 10 41
Reserves 352 269 314 405 408 513 696 876 978 1,086 1,321 1,472
14 5 1 1 18 67 112 379 266 197 204 232
87 107 188 110 113 160 181 256 240 254 324 393
Total Liabilities 462 391 512 526 550 750 1,000 1,521 1,495 1,547 1,859 2,138
153 142 202 207 213 296 343 1,059 1,121 1,177 1,447 1,601
CWIP 0 1 1 0 6 3 0 6 20 0 0 0
Investments 168 101 142 102 33 14 10 16 15 55 71 142
141 147 167 216 298 437 647 440 340 316 341 395
Total Assets 462 391 512 526 550 750 1,000 1,521 1,495 1,547 1,859 2,138

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
69 91 102 104 90 215 249 253 247 264 263 351
-56 96 -86 1 36 -104 63 -736 48 -89 -199 -223
-9 -174 -17 -87 -118 -55 -33 163 -292 -181 -87 -115
Net Cash Flow 4 14 -1 18 8 56 279 -321 3 -6 -23 12
Free Cash Flow 46 79 45 90 67 179 221 223 195 200 196 300
CFO/OP 87% 113% 109% 89% 78% 118% 106% 96% 102% 105% 99% 99%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 57 54 54 57 66 55 45 40 39 38 41 38
Inventory Days 52 46 38 53 55 44 59 68 64 58 65 51
Days Payable 92 96 97 88 90 152 160 136 136 150 171 146
Cash Conversion Cycle 17 3 -5 21 30 -54 -56 -29 -33 -53 -65 -57
Working Capital Days 32 8 -27 28 33 2 -9 -26 -22 -16 -18 16
ROCE % 28% 34% 46% 43% 43% 40% 36% 29% 17% 16% 15% 18%

Insights

In beta
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Clinical Laboratories
Number

Log in to view insights

Please log in to see hidden values.

Login
Number of Patient Visits (Millions)
Millions
Number of Tests Conducted (Millions)
Millions
Service Network points (Collection Centers/PSCs/ARCs)
Number
Revenue Per Patient (RPP)
INR

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
49.75% 49.75% 49.74% 49.67% 49.62% 49.43% 49.40% 48.89% 48.89% 48.89% 48.87% 48.86%
25.66% 24.29% 21.66% 18.90% 18.25% 18.56% 16.73% 15.29% 12.83% 12.52% 11.68% 10.43%
14.89% 16.86% 20.73% 24.86% 27.42% 28.02% 30.00% 30.30% 32.40% 33.10% 34.73% 35.80%
9.69% 9.10% 7.87% 6.57% 4.69% 3.98% 3.86% 5.51% 5.87% 5.48% 4.69% 4.92%
No. of Shareholders 89,69286,24979,87868,28358,10851,85248,57249,29350,01547,84646,67049,175

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls